<?xml version='1.0' encoding='utf-8'?>
<document id="25646154"><sentence text="Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment."><entity charOffset="0-11" id="DDI-PubMed.25646154.s1.e0" text="Angiotensin" /><entity charOffset="52-63" id="DDI-PubMed.25646154.s1.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.25646154.s1.e0" e2="DDI-PubMed.25646154.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s1.e0" e2="DDI-PubMed.25646154.s1.e1" /></sentence><sentence text="Doxorubicin (DOX) chemotherapy can cause cardiac complications"><entity charOffset="0-11" id="DDI-PubMed.25646154.s2.e0" text="Doxorubicin" /><entity charOffset="13-16" id="DDI-PubMed.25646154.s2.e1" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s2.e0" e2="DDI-PubMed.25646154.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s2.e0" e2="DDI-PubMed.25646154.s2.e1" /></sentence><sentence text=" Angiotensin converting enzyme inhibitors (ACEI) may protect against these complications"><entity charOffset="1-12" id="DDI-PubMed.25646154.s3.e0" text="Angiotensin" /></sentence><sentence text=" We performed a pharmacokinetics (PK) study to determine whether DOX levels are altered in the presence of ACEI"><entity charOffset="65-75" id="DDI-PubMed.25646154.s4.e0" text="DOX" /></sentence><sentence text="" /><sentence text="In this randomized, cross-over, single-blinded drug-drug interaction study, 19 women with breast cancer prescribed DOX and cyclophosphamide every 14 days received one cycle of DOX chemotherapy with ACEI enalapril 10 mg daily and another cycle of DOX with placebo"><entity charOffset="123-139" id="DDI-PubMed.25646154.s6.e0" text="cyclophosphamide" /><entity charOffset="115-130" id="DDI-PubMed.25646154.s6.e1" text="DOX" /><entity charOffset="176-191" id="DDI-PubMed.25646154.s6.e2" text="DOX" /><entity charOffset="246-261" id="DDI-PubMed.25646154.s6.e3" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e1" e2="DDI-PubMed.25646154.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e1" e2="DDI-PubMed.25646154.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e1" e2="DDI-PubMed.25646154.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e1" e2="DDI-PubMed.25646154.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e0" e2="DDI-PubMed.25646154.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e0" e2="DDI-PubMed.25646154.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e0" e2="DDI-PubMed.25646154.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e2" e2="DDI-PubMed.25646154.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25646154.s6.e2" e2="DDI-PubMed.25646154.s6.e3" /></sentence><sentence text=" Blood samples for DOX and doxorubicinol were drawn at baseline, 0"><entity charOffset="27-40" id="DDI-PubMed.25646154.s7.e0" text="doxorubicinol" /><entity charOffset="19-31" id="DDI-PubMed.25646154.s7.e1" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s7.e1" e2="DDI-PubMed.25646154.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25646154.s7.e1" e2="DDI-PubMed.25646154.s7.e0" /></sentence><sentence text="5, 1" /><sentence text="0, 2" /><sentence text="0, 4" /><sentence text="0, 24" /><sentence text="0 and 48" /><sentence text="0 hours after infusion with and without ACEI enalapril" /><sentence text=" Correlative laboratories were also obtained" /><sentence text=" PK data was analyzed using non compartmental methods and DOX and doxorubicinol area under the curve (AUC) 0 to infinity, Cmax and half-life were estimated"><entity charOffset="66-79" id="DDI-PubMed.25646154.s15.e0" text="doxorubicinol" /><entity charOffset="58-70" id="DDI-PubMed.25646154.s15.e1" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s15.e1" e2="DDI-PubMed.25646154.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25646154.s15.e1" e2="DDI-PubMed.25646154.s15.e0" /></sentence><sentence text=" Paired t-tests were used to determine whether DOX and its metabolite were altered with the use of enalapril (P &lt; 0"><entity charOffset="99-108" id="DDI-PubMed.25646154.s16.e0" text="enalapril" /><entity charOffset="47-55" id="DDI-PubMed.25646154.s16.e1" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s16.e1" e2="DDI-PubMed.25646154.s16.e1" /><pair ddi="false" e1="DDI-PubMed.25646154.s16.e1" e2="DDI-PubMed.25646154.s16.e0" /></sentence><sentence text="05)" /><sentence text="" /><sentence text="17 women (median age 45 years) received 60 mg/m2 DOX every two weeks for four cycles"><entity charOffset="49-51" id="DDI-PubMed.25646154.s19.e0" text="DOX" /></sentence><sentence text=" Mean (SD) AUC0- ∞ for DOX and doxorubicinol with enalapril exposure was 1185"><entity charOffset="31-44" id="DDI-PubMed.25646154.s20.e0" text="doxorubicinol" /><entity charOffset="50-59" id="DDI-PubMed.25646154.s20.e1" text="enalapril" /><entity charOffset="23-31" id="DDI-PubMed.25646154.s20.e2" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s20.e2" e2="DDI-PubMed.25646154.s20.e2" /><pair ddi="false" e1="DDI-PubMed.25646154.s20.e2" e2="DDI-PubMed.25646154.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s20.e2" e2="DDI-PubMed.25646154.s20.e1" /><pair ddi="false" e1="DDI-PubMed.25646154.s20.e0" e2="DDI-PubMed.25646154.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s20.e0" e2="DDI-PubMed.25646154.s20.e1" /></sentence><sentence text="56 (44" /><sentence text="64) hr*ng/ml and 1040 (80" /><sentence text="6) hr*ng/ml, respectively" /><sentence text=" AUC0- ∞ for DOX and doxobubicinol without enalapril was 1167"><entity charOffset="21-34" id="DDI-PubMed.25646154.s24.e0" text="doxobubicinol" /><entity charOffset="43-52" id="DDI-PubMed.25646154.s24.e1" text="enalapril" /><entity charOffset="13-21" id="DDI-PubMed.25646154.s24.e2" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s24.e2" e2="DDI-PubMed.25646154.s24.e2" /><pair ddi="false" e1="DDI-PubMed.25646154.s24.e2" e2="DDI-PubMed.25646154.s24.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s24.e2" e2="DDI-PubMed.25646154.s24.e1" /><pair ddi="false" e1="DDI-PubMed.25646154.s24.e0" e2="DDI-PubMed.25646154.s24.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s24.e0" e2="DDI-PubMed.25646154.s24.e1" /></sentence><sentence text="73 (45" /><sentence text="26) hr*ng/ml and 1056" /><sentence text="32 (92" /><sentence text="03) hr*ng/ml, respectively" /><sentence text=" There is no interaction between DOX and enalapril"><entity charOffset="41-50" id="DDI-PubMed.25646154.s29.e0" text="enalapril" /><entity charOffset="33-41" id="DDI-PubMed.25646154.s29.e1" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s29.e1" e2="DDI-PubMed.25646154.s29.e1" /><pair ddi="false" e1="DDI-PubMed.25646154.s29.e1" e2="DDI-PubMed.25646154.s29.e0" /></sentence><sentence text=" Enalapril was tolerated (33% grade 1 dizziness)"><entity charOffset="1-10" id="DDI-PubMed.25646154.s30.e0" text="Enalapril" /></sentence><sentence text="" /><sentence text="ACEI, enalapril, does not appear to alter the PK of DOX"><entity charOffset="6-15" id="DDI-PubMed.25646154.s32.e0" text="enalapril" /><entity charOffset="52-60" id="DDI-PubMed.25646154.s32.e1" text="DOX" /><pair ddi="false" e1="DDI-PubMed.25646154.s32.e0" e2="DDI-PubMed.25646154.s32.e0" /><pair ddi="false" e1="DDI-PubMed.25646154.s32.e0" e2="DDI-PubMed.25646154.s32.e1" /></sentence><sentence text=" Ongoing efforts to determine the effectiveness of ACEI as a cardioprotective agent in women receiving DOX chemotherapy should be continued"><entity charOffset="103-105" id="DDI-PubMed.25646154.s33.e0" text="DOX" /></sentence><sentence text="" /></document>